Lifeway Foods Inc. filings document the regulatory record for an Illinois operating company whose common stock trades on the Nasdaq Global Market under the symbol LWAY. Its Form 8-K reports cover operating results, sales estimates, Regulation FD disclosures, material agreements, director appointments and resignations, and compensatory arrangements under the company's 2022 Omnibus Incentive Plan.
Proxy materials describe annual shareholder meeting matters, board and committee governance, executive compensation and equity-plan administration. The filing record also identifies the company's registered securities, including common stock and preferred stock purchase rights, and includes formal disclosures related to financial reporting, governance changes and capital-structure matters.
Lifeway Foods, Inc. ownership disclosure: a group of related reporting persons led by Divisadero Street reports beneficial ownership of 2,101,540 shares of common stock, representing 13.8% of the class. The filing names Divisadero Street Capital Management, LP; Divisadero Street Partners, L.P.; Divisadero Street Partners GP, LLC; Divisadero Street Capital, LLC; and William Zolezzi as reporting persons and shows shared voting and dispositive power over the same 2,101,540 shares. Signatures are dated 05/18/2026 and the cover indicates an amendment.
Lifeway Foods, Inc. insider Edward Smolyansky, identified as a ten percent owner, reported open-market sales of a total of 49,000 shares of common stock over two days. On May 14–15, 2026, he sold shares at weighted average prices ranging from about $23.73 to $26.99 per share, according to price-range footnotes. After these sales, he continues to hold a substantial position in Lifeway Foods both directly and indirectly through a trust and an LLC, while formally disclaiming beneficial ownership of shares held by his son and limiting beneficial ownership claims on certain LLC-held shares.
Lifeway Foods, Inc. registers 3,454,756 shares of its common stock for resale by the Selling Stockholder, Danone USA Public Benefit Corporation, under a prospectus supplement to its Form S-3.
The prospectus supplement states the company will receive no proceeds from these resales, the shares are offered at a public offering price of $19.50 per share, and the underwriter will purchase the shares from the Selling Stockholder at $18.425 per share. The document also discloses that, as of April 30, 2026, there were 15,281,888 shares outstanding, that the Selling Stockholder beneficially owned 22.61% prior to the offering, and that the company has agreed, subject to completion of the offering, to repurchase up to $5 million of offered shares from the underwriter.
LWAY insider sale reports: Form 144 filings list multiple open-market sales of Common Stock by Edward Smolyansky, including transactions of 25,000 shares on 05/14/2026 and smaller lots in March 2026. The filing also notes a prior gift of 50,000 shares on 05/19/2023.
LifeWay Foods disclosure shows a proposed sale of 20,000 common shares by Michael Smolyansky, indicated as received by inheritance on 01/01/2002. The Form 144 names RBC Capital Markets LLC as broker. The filing also records recent sales by Ludmila Smolyansky: 10,000 shares sold on 03/18/2026 for $188,000 and 15,000 shares sold on 04/20/2026 for $397,500.
LWAY reported reported Form 144 sale notices for Common Stock by related parties. The filing lists a gift of 50,000 shares on 05/19/2023 to Ludmila Smolyansky and a series of sales by Edward Smolyansky in March 2026 totaling several transactions: 22,313, 13,334, 7,343 and 14,353 shares with reported proceeds shown alongside each trade.
The notices identify Citigroup Global Markets Inc. as the broker and include per‑trade proceeds in dollars for each sale. The filing is administrative disclosure of insider dispositions under Form 144.
Lifeway Foods, Inc. disclosed that Danone USA Public Benefit Corporation is conducting a secondary underwritten public offering of 3,454,756 shares of Lifeway common stock at $19.50 per share. All shares are being sold by the selling stockholder, so Lifeway will not receive offering proceeds.
Lifeway has agreed to repurchase approximately $5.0 million of these shares at the same price, with the repurchase conditioned on the closing of the offering, which is expected on May 19, 2026 subject to customary conditions. The transaction is being made under an effective Form S-3 shelf registration, with BTIG, LLC acting as sole underwriter and book-running manager.
Lifeway Foods, Inc. is registering the resale of 3,454,756 shares of Common Stock by the selling stockholder.
The shares are being offered by Danone USA Public Benefit Corporation and the company will receive no proceeds from these resales. The prospectus reflects 15,281,888 shares outstanding as of April 30, 2026. Lifeway has indicated an interest in repurchasing up to $5 million of shares from the underwriter, but that repurchase is contingent and may not occur.
Lifeway Foods reported strong first‑quarter 2026 growth, with net sales of $63.0 million, up 36.7% from a year earlier, driven mainly by higher volumes of branded drinkable kefir. Gross margin improved to 27.5% from 24.0% as milk pricing and manufacturing efficiencies supported profitability.
Income from operations rose to $6.3 million, or 10.0% of sales, compared with $1.6 million and a 3.5% margin in 2025. Net income increased to $4.7 million, or diluted earnings per share of $0.30 versus $0.23. Operating cash flow turned positive at $4.4 million.
The company invested $11.0 million in property and equipment, largely to expand and modernize its Waukesha, Wisconsin facility, a project expected to double that plant’s capacity. To help fund this, Lifeway drew $7.0 million on its $25.0 million revolving credit facility and remained in compliance with all covenants, ending the quarter with $5.6 million in cash and $18.0 million of revolver availability.
Lifeway Foods reported record results for the quarter ended March 31, 2026, with net sales of $63.0 million, up 36.7% year-over-year, driven mainly by its flagship Lifeway Kefir. Gross profit margin improved to 27.5% from 23.9%, showing better profitability on each dollar of sales.
Net income rose to $4.7 million from $3.5 million, and diluted earnings per share increased to $0.30 from $0.23. Operating cash flow improved to $4.4 million, while the company invested $11.0 million in property and equipment and drew on a $8.0 million line of credit. Management reiterated a long‑term Adjusted EBITDA target of $45–$50 million for FY 2027 and expects FY 2026 to deliver the strongest annual sales in its history.